Let’s talk about Semaglutide

Dear reader,

Let’s start with your question.

P.S.

Promise Peptides at mypromise.com offers prescription peptide therapy through licensed U.S. providers, who prescribe compounded Semaglutide. After reviewing your request, a licensed provider decides whether prescribing fits your situation; you may not qualify. U.S. patients only. Compounded medicines are not FDA-approved.

An unsealed cream envelope with folded paper and reading glasses on a pale zinc table — An envelope left open, with room for another question.

Enclosures for the conversation

1. Start with the blood-sugar question

What are you hoping semaglutide will change? That's where I'd begin. A conversation about a medicine gets easier when there's a clear reason for considering it.

Semaglutide acts like GLP-1, a gut hormone involved in blood sugar and appetite. It switches on the same kind of receiver in the body. The prescribing information explains that shared signal, without making it a reason for everyone to seek treatment.

In SUSTAIN 1, a trial in adults with type 2 diabetes, semaglutide alone lowered HbA1c more than placebo, a treatment without the active medicine. HbA1c is a marker of average blood sugar over about three months. That matters if blood sugar is the problem being discussed. It doesn't tell every reader what their goal ought to be.

A question to take along: “What are we trying to improve, and how will we check?” The letter about how it works starts there too.

2. Put the benefit beside the burden

The weight findings are real. In a study of adults without diabetes who had obesity, or overweight with a related health condition, semaglutide led to more weight loss than placebo. Both groups had lifestyle support. The average result can't predict yours. These trials tested particular study medicines; they don't establish the same results for a compounded preparation.

Side effects belong in the same conversation. The safety review describes nausea, vomiting, diarrhea and constipation. A promising result on paper can still come with a difficult time in the bathroom.

There are serious warnings too. The label for Wegovy (semaglutide injection and tablets) describes thyroid C-cell tumors in rodents, with the risk in humans unknown. It rules out use with a personal or family history of medullary thyroid cancer, or MEN 2, an inherited condition linked to certain tumors.

Another question: “Which benefit matters for me, and which warning might change the decision?” The benefits and side effects letter keeps them together.

3. Leave room for the next conversation

I'd want the exact product and the follow-up plan written down. The FDA explains that compounded medicines are not FDA-approved. The ingredient name alone doesn't tell you everything about a preparation.

I'd ask about the ending, too. In the STEP 1 extension, adults previously assigned semaglutide regained substantial weight, on average, over the year after treatment and lifestyle support stopped. That makes ongoing care worth discussing early. It doesn't decide anyone's plan to continue or stop.

The take-along list leaves space for answers about the goal, the product and what happens next. You don't need to read every letter before an appointment. One useful question is a perfectly good start.

P.S. “What would make us choose a different plan?” I'd leave a little room on the page for that answer.